Treatment with Rituximab is associated with significantly improved cutaneous sclerosis: real-world observations in an Indian cohort

View Full Paper

Ask AI

Bookmark

Rituximab treatment led to a 47.9% reduction in skin sclerosis, compared to a 31.2% reduction in the naïve group.
Among 98 SSc patients, those treated with rituximab showed better baseline mRSS scores with 70.3% having DSS.
Multivariate analysis highlighted that a greater percentage reduction in mRSS was a predictor of survival.
Overall survival at 140 months was 65.8% for the rituximab group, compared to 53.2% in the naïve group, with no survival benefit.

Discussion

No takes yet. Share an insight, caveat, or question.

Retrospective analysis shows rituximab reduced skin sclerosis in SSc patients, suggesting potential benefits for treatment.

Handa et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark